Prostate Cancer

Receipt of guideline-recommended surveillance in a population-based cohort of active surveillance prostate cancer patients.

Prospective clinical trials have demonstrated the safety and efficacy of active surveillance for men with localized prostate cancer, but also suggested that inadequate surveillance may risk missing an opportunity for cure.

Bioinformatic analysis of dysregulated proteins in prostate cancer patients reveals putative urinary biomarkers and key biological pathways.

Prostate cancer (PCa) is one of the most common cancer types among men. The quantification of prostate-specific antigen used for PCa detection has revealed limited applicability. Thus, it is crucial to identify new minimally invasive biomarkers for PCa.

Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy.

To evaluate the clinical characteristics of genuine- and induced-oligometastatic castration-resistant prostate cancer (OM-CRPC) and assess the therapeutic effect of progressive-site directed therapy (PSDT).

Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells.

Prostate cancer (PCa) is dependent on the androgen receptor (AR). Advanced PCa is treated with an androgen deprivation therapy-based regimen; tumors develop resistance, although they typically remain AR-dependent.

Differences in Implementation Outcomes of a Shared Decision-Making Program for Men with Prostate Cancer between an Academic Medical Center and County Health Care System.

Shared decision making (SDM) has long been advocated as the preferred way for physicians and men with prostate cancer to make treatment decisions. However, the implementation of formal SDM programs in routine care remains limited, and implementation outcomes for disadvantaged populations are especially poorly described.

Early-Onset Metastatic and Clinically Advanced Prostate Cancer Is a Distinct Clinical and Molecular Entity Characterized by Increased TMPRSS2-ERG Fusions - Beyond the Abstract

Prostate cancer is the leading cancer diagnosis among men in the United States with an estimated 248,530 new cases expected and is the second most common cause of cancer death for men in the United States, responsible for an estimated 34,130 deaths in 2021.1 It is a heterogeneous disease with locoregional cancers carrying an excellent five-year overall survival of nearly 100% in stark contrast to aggressive and lethal phenotypes that carry poor outcomes despite advances in systemic therapy. The rising incidence of young men presenting with aggressive disease phenotypes has been particularly challenging for the medical community,2 and our study, therefore, sought to describe the clinical and molecular features of early-onset prostate cancer on a large scale.

PI-RADS 3 Lesions: Does the Association of the Lesion Volume with the Prostate-Specific Antigen Density Matter in the Diagnosis of Clinically Significant Prostate Cancer? - Beyond the Abstract

A new subclassification of the Pi-RADS 3 lesions was recently published and two subgroups have been suggested: 3a (indolent or low-risk lesions with volume <0.5 ml) and 3b (significant or high-risk lesions with volume ≥0.5 ml).1

Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.

Rationale: Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule positron emission tomography (PET) radiotracer targeting prostate-specific membrane antigen (PSMA).

Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.

Multiple systemic treatments are available for metastatic castration-sensitive prostate cancer (mCSPC), with unclear comparative effectiveness and safety and widely varied costs.

To compare the effectiveness and safety determined in randomized clinical trials of systemic treatments for mCSPC.

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.

Liquid biopsy-based biomarkers have advantages in monitoring the dynamics of metastatic castration-resistant prostate cancer (mCRPC), a bone-predominant metastatic disease. Previous studies have demonstrated associations between circulating tumor cells (CTCs) and clinical outcomes of mCRPC patients, but little is known about the prognostic value of CTC-clusters.